Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application source : Investors.biomarin.com save search
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
Published: 2023-03-07 (Crawled : 22:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: 0.12%
H: 1.14%
C: 0.83%
voxzogo fda drug children application achondroplasia injection
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
Published: 2023-01-03 (Crawled : 22:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: 3.06%
H: 3.12%
C: 3.12%
voxzogo children extension application injection achondroplasia
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
Published: 2022-10-12 (Crawled : 21:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: -1.7%
H: 3.35%
C: 2.24%
fda application license therapy
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
Published: 2022-09-29 (Crawled : 20:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: -0.08%
H: 2.07%
C: -0.26%
fda application license therapy
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-07-15 (Crawled : 13:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: -0.36%
H: 0.76%
C: 0.23%
europe authorized application
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-06-28 (Crawled : 13:00) - investors.biomarin.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: 1.18%
H: 0.63%
C: -1.59%
europe authorized application
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.